FGFR1 Overexpression Common in Adult Patients With Soft Tissue Sarcoma

Share this content:
Fibroblast growth factor receptor 1 amplification and overexpression are common events in multiple subtypes of soft tissue sarcoma.
Fibroblast growth factor receptor 1 amplification and overexpression are common events in multiple subtypes of soft tissue sarcoma.

Fibroblast growth factor receptor 1 (FGFR1) amplification and overexpression are common events in multiple subtypes of soft tissue sarcoma, and high FGFR1-expressing soft tissue sarcoma cells are sensitive to FGFR inhibitors.1

Because high-level FGFR1 amplification was detected in a patient with metastatic leiomyosarcoma, a type of soft tissue sarcoma, researchers in Germany sought to investigate the role of FGFR1 as an oncogenic driver and potential therapeutic target in soft tissue sarcoma.

For the study, researchers assessed the frequency of FGFR1 amplification and overexpression in a cohort of 176 patients with treatment-naïve high-grade soft tissue sarcoma and validated their results using data from 256 patients included in The Cancer Genome Atlas (TCGA). They also evaluated the sensitivity of FGFR1-altered soft tissue sarcoma cells to genetic and pharmacologic FGFR1 inhibition.

Results showed FGFR1 amplification and overexpression were present in 31% and 34% of cases in the 176 untreated patients with high-grade soft tissue sarcoma and in 16% and 15% of cases in the TCGA cohort, respectively. Of note, researchers detected FGFR1 overexpression without amplification in a substantial proportion of cases.

Furthermore, researchers found that high FGFR1-expressing soft tissue sarcoma cells were sensitive to FGFR inhibition by inhibitors that include PD173074, AZD4547, and BGJ398. The study demonstrated that the degree of dependence on FGFR1 for proliferation, survival, and growth was primary influenced by FGFR1 expression levels.

RELATED: Nomograms Can Predict OS, Distant Metastases in Soft-tissue Sarcomas

These findings ultimately supported FGFR1 as a novel therapeutic target in soft tissue sarcoma and suggested that FGFR1 overexpression was a more reliable biomarker of sensitivity to FGFR pathway inhibition compared with genomic amplification.

Reference

  1. Chudasama P, Renner M, Specht K, et al. FGFR1 overexpression is frequent in adult soft tissue sarcoma and predicts sensitivity to FGFR inhibitors. Poster presentation at: AACR Annual Meeting 2016; April 16-20, 2016; New Orleans, LA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs